本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 潘讴东先生为公司实际控制人，截至本公告披露日，潘讴东先生直接持有公司122,805,540股股份，占公 司总股本的18.92%。潘讴东先生辞任总经理后继续担任董事长等职务，将继续遵守法律、法规和规范 性文件的相关规定及所作出的相关承诺。 潘讴东先生在担任公司总经理期间勤勉尽责、恪尽职守，公司及董事会对潘讴东先生在担任公司总经理 期间为公司经营发展做出的贡献表示衷心感谢！ ●和元生物技术（上海）股份有限公司（以下简称"公司"）董事会于近日收到总经理潘讴东先生辞去总 经理职务的书面辞呈。潘讴东先生因计划更专注于履行董事长职责，集中精力统筹公司长期战略规划与 发展方向，进一步优化公司治理结构、提升决策效率，申请不再兼任公司总经理职务。辞任后，潘讴东 先生将继续担任第四届董事会董事长、第四届董事会战略与ESG委员会主任委员、第四届董事会薪酬与 考核委员会委员、第四届董事会提名委员会委员。 ●公司于2025年12月29日召开第四届董事会第五次会议，审议通过了《关于变更公司总 ...

Core Points - The candidate, Hao Mei, has declared their qualifications and commitment to serve as an independent director for Yuan Biotechnology (Shanghai) Co., Ltd. [1] - The candidate possesses the necessary knowledge of company operations and relevant laws, with over five years of experience in legal, economic, accounting, and management fields [1] - The candidate confirms independence and does not fall under any disqualifying conditions as outlined by relevant regulations [1][2] Summary by Sections - **Qualifications**: The candidate meets the requirements set by various laws and regulations, including the Company Law of the People's Republic of China and the Management Measures for Independent Directors issued by the China Securities Regulatory Commission [1] - **Independence**: The candidate asserts independence, stating no direct or indirect relationships that could compromise their role, including not holding significant shares or positions in related companies [1] - **No Disciplinary Records**: The candidate has no adverse records in the last 36 months, including no administrative penalties from the China Securities Regulatory Commission or criminal charges [2][3] - **Commitment to Responsibilities**: The candidate acknowledges the responsibilities of an independent director and commits to adhering to all relevant laws and regulations, ensuring sufficient time and effort to fulfill their duties [4]

Core Points - The company, He Yuan Biotechnology (Shanghai) Co., Ltd., was established as a joint-stock company in accordance with the Company Law of the People's Republic of China and is registered with the Shanghai Municipal Market Supervision Administration [1][2] - The company was approved by the Shanghai Stock Exchange on November 4, 2021, and registered with the China Securities Regulatory Commission on January 11, 2022, for its initial public offering of 100 million shares, which were listed on the STAR Market on March 22, 2022 [2] - The registered capital of the company is RMB 649.0367 million [2] - The company aims to develop high-tech industries and expand both domestic and international markets while ensuring reasonable returns for shareholders and creating positive social effects [6] Company Structure - The company is a permanent joint-stock company, with the board of directors acting as the legal representative [2][3] - The legal representative is responsible for civil activities conducted in the company's name, and the company bears civil liability for actions taken by the legal representative [3] - Shareholders are liable for the company's debts only to the extent of their subscribed shares, while the company is liable for its debts with all its assets [3] Business Operations - The company's business scope includes drug production, entrusted drug production, and various technical services in the biomedical field [6] - The company operates under principles of honesty and legality, aiming to optimize management and develop high-tech industries [6] Share Issuance and Management - The company issues registered shares, all of which are ordinary shares, with a total of 649.0367 million shares issued [7] - The shares are stored in a centralized manner at the Shanghai branch of China Securities Depository and Clearing Corporation Limited [7] - The company can increase its registered capital through various methods, including issuing shares to unspecified or specific objects, subject to shareholder approval [9] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, and other benefits proportional to their shareholdings [15] - Shareholders are required to comply with laws and the company's articles of association, and they cannot withdraw their capital except as permitted by law [20] - The company has provisions for shareholders to propose and vote on various matters, including the election of directors and approval of financial reports [23][29] Governance and Meetings - The company holds annual and extraordinary shareholder meetings, with specific procedures for calling and conducting these meetings [48][52] - The board of directors is responsible for convening shareholder meetings and ensuring compliance with legal and regulatory requirements [52][54] - Shareholder meetings must be documented, and records must be maintained for a minimum of 10 years [78]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 上述回购股份进展符合相关法律法规的规定及公司回购股份方案的要求。 三、其他事项 ■ 一、回购股份的基本情况 2025年2月13日，公司召开第三届董事会第十八次会议，审议通过了《关于以集中竞价交易方式回购股 份方案的议案》，同意公司以自有资金及股票回购专项贷款，通过上海证券交易所交易系统以集中竞价 交易方式回购公司已发行的部分人民币普通股（A股）股份，回购股份在未来适宜时机用于股权激励或 员工持股计划，以及维护公司价值及股东权益。本次回购价格不高于人民币7.00元/股（含），回购资 金总额不低于人民币5,000万元（含），不超过人民币10,000万元（含）。本次回购股份的实施期限为自 公司董事会审议通过本次回购方案之日起3个月内。 具体内容详见刊载于上海证券交易所网站（www.sse.com.cn）的《和元生物技术（上海）股份有限公司 关于以集中竞价交易方式回购股份方案的公告》（公告编号：2025-010）、《和元生物技术（上海 ...